Gossamer Bio, Inc. (NASDAQ:GOSS) Given Average Rating of “Hold” by Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has been given an average recommendation of “Hold” by the ten research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $4.50.

A number of analysts recently commented on the stock. Weiss Ratings downgraded shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. HC Wainwright reduced their price target on shares of Gossamer Bio from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Thursday, June 25th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Gossamer Bio in a research note on Monday, March 23rd.

Gossamer Bio Stock Performance

GOSS traded down $0.01 during trading on Tuesday, hitting $0.18. The stock had a trading volume of 6,518,759 shares, compared to its average volume of 13,813,055. The firm has a market capitalization of $42.48 million, a P/E ratio of -0.23 and a beta of 2.04. The company’s 50-day moving average price is $0.23 and its 200 day moving average price is $1.12. Gossamer Bio has a twelve month low of $0.14 and a twelve month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $16.95 million for the quarter, compared to analysts’ expectations of $4.67 million. As a group, equities analysts expect that Gossamer Bio will post -0.37 earnings per share for the current fiscal year.

Institutional Trading of Gossamer Bio

Large investors have recently bought and sold shares of the company. Corient Private Wealth LLC increased its stake in shares of Gossamer Bio by 19,123.7% during the 4th quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after purchasing an additional 3,825,879 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in Gossamer Bio in the 4th quarter valued at approximately $148,000. Merit Financial Group LLC grew its holdings in Gossamer Bio by 15.2% during the 4th quarter. Merit Financial Group LLC now owns 155,178 shares of the company’s stock valued at $481,000 after buying an additional 20,490 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Gossamer Bio during the 4th quarter valued at $35,000. Finally, CWM LLC raised its holdings in shares of Gossamer Bio by 35.7% in the fourth quarter. CWM LLC now owns 33,957 shares of the company’s stock worth $105,000 after acquiring an additional 8,940 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.